Welcome to our dedicated page for Accelerate Diagnostics SEC filings (Ticker: AXDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This archive contains SEC filings for Accelerate Diagnostics Inc (AXDX), which previously operated in the in vitro diagnostics sector before filing for Chapter 11 bankruptcy and ceasing operations as a publicly traded company. These historical regulatory documents provide a comprehensive record of the company's financial performance, business operations, and the circumstances leading to its bankruptcy filing.
The company's 10-K annual reports detail its rapid diagnostic technology development, revenue from system placements and test consumables, research and development expenditures, and the operational challenges faced in commercializing laboratory instrumentation. Quarterly 10-Q filings track the company's cash position, revenue trends, and evolving business strategy as it worked to achieve commercial viability.
Form 8-K filings document material events including FDA clearances for diagnostic systems, financing activities, and ultimately the bankruptcy proceedings. Form 4 insider transaction filings reveal executive and director stock transactions during the company's operating period. The NT 10-Q late filing notifications and Form 25-NSE delisting notice provide insight into the final stages of the company's deteriorating financial condition.
These archived SEC documents serve as a historical record for understanding the financial trajectory and operational challenges faced by specialized medical device companies attempting to compete in the in vitro diagnostics market against larger, more diversified laboratory equipment manufacturers.
Accelerate Diagnostics, Inc. and its U.S. subsidiary filed voluntary Chapter 11 petitions and have entered an amended and restated Asset Purchase Agreement with an affiliate of Indaba Capital Management for the planned sale of company assets. The A&R Purchase Agreement narrows the buyer's acquisition to certain assets and liabilities rather than "substantially all" assets. The Bankruptcy Court entered a Confirmation Order approving the Second Amended Combined Disclosure Statement and Chapter 11 Plan of Liquidation, and the Company Parties intend to effect the transactions contemplated by the Plan after satisfaction or waiver of the Plan's conditions.
Nasdaq Stock Market LLC has filed Form 25 to remove Accelerate Diagnostics, Inc. (AXDX) common stock from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. The notice, signed on 2025-07-21 by Hearings Advisor Aravind Menon, states that Nasdaq believes it meets all requirements for the filing. The company’s securities will cease to be listed once the Form 25 becomes effective and the Exchange Act registration will be withdrawn unless the SEC objects. No financial or earnings data accompany this low-complexity filing; the sole purpose is the formal delisting of AXDX shares.
Gilbert E. Nathan has filed a Form 3 (Initial Statement of Beneficial Ownership) following his appointment as Director at Accelerate Diagnostics (AXDX). The filing, dated June 28, 2025, discloses Nathan's beneficial ownership position as of April 10, 2025.
Key details from the filing:
- Nathan currently holds no securities (derivative or non-derivative) beneficially owned in the company
- The filing confirms his position as Director but indicates no other roles such as Officer or 10% Owner
- This is an individual filing, not a joint/group submission
- Business address is listed as 3950 S. Country Club Road, Suite 470, Tucson, AZ 85714
This Form 3 filing is a standard regulatory requirement for new directors under Section 16(a) of the Securities Exchange Act of 1934, establishing a baseline for future ownership reporting.
FAQ
What is the current stock price of Accelerate Diagnostics (AXDX)?
What is the market cap of Accelerate Diagnostics (AXDX)?
